The mTOR pathway is often hyperactivated in cancer due to mutations in upstream regulators like PI3K/AKT, leading to uncontrolled cell growth and survival. mTOR inhibitors can disrupt this pathway, thereby slowing down or even halting the progression of cancer cells. This makes mTOR an attractive target for anticancer therapies.
